Baxter International restarted its highest-throughput intravenous solutions manufacturing line at its hurricane-hit North Cove facility in North Carolina, the company announced Thursday.
At its peak operation, prior to Hurricane Helene, manufacturing line represented approximately 25% of the site’s total production and approximately 50% of the site’s production of one-liter IV solutions, the most commonly used size by hospitals and clinics.
Baxter said initial batches will be manufactured concurrently with ongoing quality activities and will only be released in accordance with applicable regulatory requirements to ensure the quality and safety of the products.
“Recovery progress at our North Cove site continues to be very encouraging. In a matter of weeks, our team has advanced from the depths of Hurricane Helene’s impact to restarting our highest-throughput manufacturing line. This is a pivotal milestone, but more hard work remains as we work to return the plant to full production,” José E. Almeida, chair, Baxter International president and chief executive officer said in a statement. “I want to recognize the dedication of our North Cove team as well as the countless Baxter employees globally who have committed themselves to helping contribute to supply continuity amid this unprecedented challenge. I also offer Baxter’s gratitude for the steadfast support of ASPR, FDA, the State of North Carolina and HHS. And we are deeply appreciative of our customers’ patience and partnership as progress continues.”
Continue to the full article here.